Caribou Biosciences appoints Dara Richardson-Heron to board and Ruhi Khan as Chief Business Officer
Caribou Biosciences, Inc.
Dara Richardson-Heron, M.D., appointed as Class III director effective Nov 4, 2021, and to Nominating Committee.
Ruhi Khan appointed as Chief Business Officer, bringing 20+ years of biotech business development experience.
Board size increased from six to seven directors to accommodate Richardson-Heron's appointment.
Richardson-Heron receives standard director compensation: $40K/yr cash plus $4K/yr for committee; initial option for 44,000 shares vesting over 3 years.
On November 4, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from six to seven directors and unanimously agreed to extend an offer to Dara Richardson-Heron, M.D., to serve as a Class III director of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Dara Richardson-Heron was appointed as Class III Director at Caribou Biosciences, Inc..
Action
appointed
Role
Class III Director
Exact text from the filing
On November 4, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from six to seven directors and unanimously agreed to extend an offer to Dara Richardson-Heron, M.D., to serve as a Class III director of the Company.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.